United Kingdom

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

23 May 2018
Change (% chg)

$4.96 (+42.76%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Cara Therapeutics Inc reports Q3 loss per share $0.38
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Cara Therapeutics Inc :Cara Therapeutics Inc reports third quarter 2017 financial results.Q3 loss per share $0.38.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Cara Therapeutics Inc - expects existing cash and cash equivalents, among others to be sufficient to fund operating expenses, capex requirements into 2019​.  Full Article

Cara therapeutics posts Q2 shr loss $0.48
Thursday, 4 Aug 2016 

Cara Therapeutics Inc : Q2 loss per share $0.48 . Cara therapeutics reports second quarter 2016 financial results .Q2 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.  Full Article

Cara Therapeutics resumes patient recruitment
Monday, 6 Jun 2016 

Cara Therapeutics Inc : Resumed patient recruitment after FDA removed clinical hold on CLIN3001 adaptive phase 3 trial of I.V. CR845 for postoperative pain . Study will continue as a three-arm trial comparing two doses of CR845 (1.0 and 0.5 ug/kg) to placebo . To provide updates on progress of trial later this year .Cara Therapeutics resumes patient recruitment for adaptive phase 3 trial of I.V. CR845 in postoperative pain.  Full Article

Cara Therapeutics signs licensing deal with Vifor Fresenius, shares surge

Shares of Cara Therapeutics surged more than 20 percent on Wednesday after it signed a licensing agreement with Vifor Fresenius Medical Care Renal Pharma Ltd that could give the U.S. drug developer up to $470 million in milestone payments.